![Quiver Logo](/static/img/logo-icon.png)
![IMAB logo](https://quiver-logos.s3.us-east-2.amazonaws.com/imab.png)
I-MAB American Depositary Shares
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view IMAB Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Recent trades of IMAB by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by IMAB's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Recent insights relating to IMAB
Recent picks made for IMAB stock on CNBC
ETFs with the largest estimated holdings in IMAB
Flights by private jets registered to IMAB
![Quiver Logo](/static/img/logo-icon.png)